Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

Pfizer Inc. (PFE) Stock Price: $25.70+0.08 (+0.31%)

The total return cagr for Pfizer Inc. (PFE) stock is 14.76% over the past 12 months. The 3 year average growth rate is -7.34% and the 5 year cagr is -3.54%. Total return includes dividends reinvested.

The closing share price for Pfizer Inc. (PFE) stock was $25.70 for Tuesday, June 9, 2026, up +0.31% from the previous day.

PFE Price Chart

End-of-day pricesAdvanced chart →
PFE$25.70 7.08%as of Jun 9, 2026

PFE Earnings Preview

Next Earnings Date

Jul 29, 2026

50 days away

EPS Estimate

0.68

Revenue Est.

$14.44B

Last Quarter Results

EPS

$0.75

vs Estimate

$0.72

Beat

Revenue

$14.45B

vs Estimate

$13.84B

Beat

PFE Analyst Ratings

Consensus Rating

Hold

Based on 27 analysts

Strong Buy
2
Buy
9
Hold
15
Sell
1
Strong Sell
2

Average Price Target

$29.19

+13.6% upside

Low

$24.00

Current

$25.70

High

$36.00

PFE Analyst Estimates

Forward P/E: 9.07

Earnings Per Share (EPS) Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2026N/A$0.72N/A13
Q2 2026N/A$0.68N/A12
Q3 2026N/A$0.85N/A11
Q4 2026N/A$0.69N/A9

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$2.83N/A14
FY 2028N/A$2.43N/A6

Revenue Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2026N/A$13.84BN/A13
Q2 2026N/A$14.44BN/A12
Q3 2026N/A$16.23BN/A11
Q4 2026N/A$16.78BN/A9

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$59.20BN/A14
FY 2028N/A$54.70BN/A6

Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.

PFE Competitors' Key Metrics

StockMarket CapClose PricePrice ChangeTTM Total Return5Y CAGR10Y CAGR
1PFE$146.48B$25.70+0.31%+14.76%-3.54%+1.93%

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla